利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

57 条记录 (耗时 0.084 秒)

    Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
    35.
    发明申请
    Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease 审中-公开
    Nectin 4，semaphorin 4b，igf9和kiaa0152调节剂用于治疗疾病的组合物和使用方法

    公开(公告)号：US20090214517A1

    公开(公告)日：2009-08-27

    申请号：US11658412

    申请日：2005-07-27

    申请人： Justin Wong ,  Kevin Hestir ,  Ernestine Lee

    发明人： Justin Wong ,  Kevin Hestir ,  Ernestine Lee

    IPC分类号： A61K39/395 ,  A61P35/00

    CPC分类号： C07K14/4703

    摘要： Microarray analysis, confirmed by RT-PCT, demonstrated that mRNA derived from cancerous tissues hybridized specifically and preferentially to human nectin 4, semaphorin 4b, IgSF9, and KIAA0152. Microarray analysis also demonstrated that RNA from malignant bladder, pancreas, and stomach tissue hybridized specifically to human nectin 4, semaphorin 4b, IgSF9, and KIAA0152, all of which are transmembrane proteins that provide a therapeutic target for treating cancer. Modulators of nectin 4, semaphorin 4b, IgSF9, and KIAA0152 are provided for the diagnosis and treatment of proliferative disorders such as cancer and psoriasis. The invention further provides methods of treating cancer with therapeutic agents directed toward nectin 4, semaphorin 4b, IgSF9, and KIAA0152.

    摘要翻译： 通过RT-PCT证实的微阵列分析表明，衍生自癌组织的mRNA特异性地优先与人Nectin 4，信号素4b，IgSF9和KIAA0152杂交。 微阵列分析还表明，来自恶性膀胱，胰腺和胃组织的RNA与人Nectin 4，信号素4b，IgSF9和KIAA0152特异性杂交，所有这些都是提供治疗癌症治疗靶标的跨膜蛋白。 提供了Nectin 4，semaphorin 4b，IgSF9和KIAA0152的调节剂用于诊断和治疗增殖性疾病如癌症和牛皮癣。 本发明还提供了针对nectin 4，semaphorin 4b，IgSF9和KIAA0152的治疗剂治疗癌症的方法。

    FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same
    36.
    发明授权
    FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same 有权
    FZD8细胞外结构域和FZD8细胞外结构域融合分子及其处理方法

    公开(公告)号：US08431532B2

    公开(公告)日：2013-04-30

    申请号：US13169900

    申请日：2011-06-27

    申请人： Thomas Brennan ,  Ernestine Lee ,  Steven Smith

    发明人： Thomas Brennan ,  Ernestine Lee ,  Steven Smith

    IPC分类号： A61K38/17

    CPC分类号： A61K38/17 ,  C07K14/71 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/42

    摘要： Methods of treatment using Fzd8 extracellular domains (ECDs), Fzd8 ECD fusion molecules, and/or antibodies that bind Fzd8 are provided. Such methods include, but are not limited to, methods of treating obesity and obesity-related conditions. Fzd8 ECDs and Fzd8 ECD fusion molecules are also provided. Polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules are provided. Methods of making and using Fzd8 ECDs, Fzd8 ECD fusion molecules, and antibodies that bind Fzd8 are also provided.

    摘要翻译： 提供了使用Fzd8细胞外结构域（ECD），Fzd8 ECD融合分子和/或结合Fzd8的抗体的治疗方法。 这些方法包括但不限于治疗肥胖症和肥胖相关病症的方法。 还提供Fzd8 ECDs和Fzd8 ECD融合分子。 提供了多肽和多核苷酸序列，载体，宿主细胞和包含或编码这些分子的组合物。 还提供了制备和使用Fzd8 ECDs，Fzd8 ECD融合分子和结合Fzd8的抗体的方法。

    ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them
    37.
    发明授权
    ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them 有权
    ECD羧基末端缺失FGFR4融合蛋白及其制备方法

    公开(公告)号：US08173134B2

    公开(公告)日：2012-05-08

    申请号：US13157712

    申请日：2011-06-10

    申请人： Elizabeth Bosch ,  Diane Hollenbaugh ,  Ernestine Lee ,  Minmin Qin ,  Ali Sadra

    发明人： Elizabeth Bosch ,  Diane Hollenbaugh ,  Ernestine Lee ,  Minmin Qin ,  Ali Sadra

    IPC分类号： C12P21/02 ,  A61K39/00 ,  C12N5/10 ,  C12N15/00 ,  C07H21/04

    CPC分类号： C07K14/71 ,  A61K45/06 ,  C07K14/765 ,  C07K16/2863 ,  C07K17/08 ,  C07K2319/30 ,  C07K2319/32

    摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

    摘要翻译： 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。